What is PhoreMost?
PhoreMost, established in 2014 and headquartered in Cambridge, United Kingdom, is at the forefront of developing a next-generation phenotypic screening platform. The company's innovative approach aims to revolutionize drug discovery and development by providing advanced tools for biological research. Its focus on phenotypic screening positions it as a key player in the biotechnology and pharmaceutical research sectors, offering solutions that accelerate the identification of novel therapeutic candidates.
How much funding has PhoreMost raised?
PhoreMost has raised a total of $68.8M across 3 funding rounds:
Angel/Seed
$3.8M
Series A
$15M
Series B
$50M
Angel/Seed (2015): $3.8M with participation from Cambridge Enterprise
Series A (2018): $15M, investors not publicly disclosed
Series B (2024): $50M supported by Jonathan Milner, Astellas Venture Management, Parkwalk Advisors, XtalPi, BGF, o2h ventures, The Morningside Group, and Trend Investments Group
Key Investors in PhoreMost
Astellas Venture Management
Astellas Venture Management is an investment arm likely focused on identifying and supporting innovative companies within the life sciences and healthcare sectors, aligning with Astellas Pharma's broader pharmaceutical interests.
Parkwalk Advisors
Parkwalk Advisors is a prominent UK-based investor specializing in university spinouts and deeptech innovations, providing crucial funding and strategic support to early-stage technology companies.
BGF
BGF is a leading investor in UK small and mid-sized businesses, providing growth capital and strategic guidance across diverse sectors to support companies in their expansion phases.
What's next for PhoreMost?
The substantial enterprise-level funding, particularly the recent major strategic investment, signals a pivotal growth phase for PhoreMost. This capital infusion is expected to fuel the expansion of its phenotypic screening platform, enhance its research and development capabilities, and potentially broaden its market reach. The company is poised to leverage this financial backing to solidify its position and drive innovation within the competitive drug discovery ecosystem.
See full PhoreMost company page
